From the article gophie posted:
"Bacteria often improperly fold complex proteins, leading to involved and expensive refolding processes, and both bacteria and yeast lack adequate post-translational modification machinery for mammalian-specific N- and O-linked glycosylation, γ-carboxylation, and proteolytic processing. Cell culture systems require high initial capital expenditures, lack scale-up (or down) flexibility, and use large volumes of culture media. On the other hand, transgenic livestock can be maintained and scaled-up in relatively inexpensive facilities, use animal feed as raw material, and can achieve impressive yields of recombinant proteins."
If I'm reading this correctly, it would seem to me that prospective partners would stand to make more money teaming with GTC than a company like GlycoFi (MRK). Coincidentally (or perhaps prophetically), Dew just questioned (Post #690) when GlycoFi would have to speak on comparing yeast vs. animals.
Best regards,
Geoff
News 
Market Data 
Discover 
